Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS

Courtney V. Fletcher, Brian K. Goodroad, Larry M. Cummins, Keith Henry, Henry H. Balfour, Frank S. Rhame

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hyperimmune anti-human immunodeficiency virus immunoglobin (HIVIG) is an intravenous immunoglobulin prepared from HIV-infected asymptomatic donuts with a CD4 cell count greater than 400 cells/μl and a high tiler of antibody to HIV-1 p24 protein. Twelve persons with AIDS received four doses of HIVIG (two at 50 mg/kg of body weight and then two at 200 mg/kg) every 28 days. Pharmacokinetics were evaluated by measurement of anti-p24 antibody. HIVIG was well tolerated, and all participants completed the study. Three subjects who were not receiving Pneumocystis carinii pneumonia (PCP) prophylaxis developed PCP. The mean value for HIVIG clearance was 3.02 ml/kg/day at 50 mg/kg and 3.65 ml/kg/day at 200 mg/kg (P = 0.027); the mean trough antibody titers (reciprocal units) were 1,442 and 4,428, respectively. This study indicates that high tilers of anti-p24 antibody can be maintained with a monthly administration schedule of HIVIG and that short-term safety is acceptable. Comparisons to evaluate the therapeutic potential of HIVIG are justified.

Original languageEnglish (US)
Pages (from-to)1571-1574
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume41
Issue number7
StatePublished - Jul 1 1997

Fingerprint

Immunoglobulins
Acquired Immunodeficiency Syndrome
Pharmacokinetics
HIV
Pneumocystis Pneumonia
Anti-Idiotypic Antibodies
Antibodies
Intravenous Immunoglobulins
CD4 Lymphocyte Count
HIV-1
Appointments and Schedules
Body Weight
Safety
Proteins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Fletcher, C. V., Goodroad, B. K., Cummins, L. M., Henry, K., Balfour, H. H., & Rhame, F. S. (1997). Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. Antimicrobial Agents and Chemotherapy, 41(7), 1571-1574.

Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. / Fletcher, Courtney V.; Goodroad, Brian K.; Cummins, Larry M.; Henry, Keith; Balfour, Henry H.; Rhame, Frank S.

In: Antimicrobial Agents and Chemotherapy, Vol. 41, No. 7, 01.07.1997, p. 1571-1574.

Research output: Contribution to journalArticle

Fletcher, CV, Goodroad, BK, Cummins, LM, Henry, K, Balfour, HH & Rhame, FS 1997, 'Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS', Antimicrobial Agents and Chemotherapy, vol. 41, no. 7, pp. 1571-1574.
Fletcher, Courtney V. ; Goodroad, Brian K. ; Cummins, Larry M. ; Henry, Keith ; Balfour, Henry H. ; Rhame, Frank S. / Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. In: Antimicrobial Agents and Chemotherapy. 1997 ; Vol. 41, No. 7. pp. 1571-1574.
@article{b684902c061d46a9a17e01b76fb46438,
title = "Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS",
abstract = "Hyperimmune anti-human immunodeficiency virus immunoglobin (HIVIG) is an intravenous immunoglobulin prepared from HIV-infected asymptomatic donuts with a CD4 cell count greater than 400 cells/μl and a high tiler of antibody to HIV-1 p24 protein. Twelve persons with AIDS received four doses of HIVIG (two at 50 mg/kg of body weight and then two at 200 mg/kg) every 28 days. Pharmacokinetics were evaluated by measurement of anti-p24 antibody. HIVIG was well tolerated, and all participants completed the study. Three subjects who were not receiving Pneumocystis carinii pneumonia (PCP) prophylaxis developed PCP. The mean value for HIVIG clearance was 3.02 ml/kg/day at 50 mg/kg and 3.65 ml/kg/day at 200 mg/kg (P = 0.027); the mean trough antibody titers (reciprocal units) were 1,442 and 4,428, respectively. This study indicates that high tilers of anti-p24 antibody can be maintained with a monthly administration schedule of HIVIG and that short-term safety is acceptable. Comparisons to evaluate the therapeutic potential of HIVIG are justified.",
author = "Fletcher, {Courtney V.} and Goodroad, {Brian K.} and Cummins, {Larry M.} and Keith Henry and Balfour, {Henry H.} and Rhame, {Frank S.}",
year = "1997",
month = "7",
day = "1",
language = "English (US)",
volume = "41",
pages = "1571--1574",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS

AU - Fletcher, Courtney V.

AU - Goodroad, Brian K.

AU - Cummins, Larry M.

AU - Henry, Keith

AU - Balfour, Henry H.

AU - Rhame, Frank S.

PY - 1997/7/1

Y1 - 1997/7/1

N2 - Hyperimmune anti-human immunodeficiency virus immunoglobin (HIVIG) is an intravenous immunoglobulin prepared from HIV-infected asymptomatic donuts with a CD4 cell count greater than 400 cells/μl and a high tiler of antibody to HIV-1 p24 protein. Twelve persons with AIDS received four doses of HIVIG (two at 50 mg/kg of body weight and then two at 200 mg/kg) every 28 days. Pharmacokinetics were evaluated by measurement of anti-p24 antibody. HIVIG was well tolerated, and all participants completed the study. Three subjects who were not receiving Pneumocystis carinii pneumonia (PCP) prophylaxis developed PCP. The mean value for HIVIG clearance was 3.02 ml/kg/day at 50 mg/kg and 3.65 ml/kg/day at 200 mg/kg (P = 0.027); the mean trough antibody titers (reciprocal units) were 1,442 and 4,428, respectively. This study indicates that high tilers of anti-p24 antibody can be maintained with a monthly administration schedule of HIVIG and that short-term safety is acceptable. Comparisons to evaluate the therapeutic potential of HIVIG are justified.

AB - Hyperimmune anti-human immunodeficiency virus immunoglobin (HIVIG) is an intravenous immunoglobulin prepared from HIV-infected asymptomatic donuts with a CD4 cell count greater than 400 cells/μl and a high tiler of antibody to HIV-1 p24 protein. Twelve persons with AIDS received four doses of HIVIG (two at 50 mg/kg of body weight and then two at 200 mg/kg) every 28 days. Pharmacokinetics were evaluated by measurement of anti-p24 antibody. HIVIG was well tolerated, and all participants completed the study. Three subjects who were not receiving Pneumocystis carinii pneumonia (PCP) prophylaxis developed PCP. The mean value for HIVIG clearance was 3.02 ml/kg/day at 50 mg/kg and 3.65 ml/kg/day at 200 mg/kg (P = 0.027); the mean trough antibody titers (reciprocal units) were 1,442 and 4,428, respectively. This study indicates that high tilers of anti-p24 antibody can be maintained with a monthly administration schedule of HIVIG and that short-term safety is acceptable. Comparisons to evaluate the therapeutic potential of HIVIG are justified.

UR - http://www.scopus.com/inward/record.url?scp=0030805675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030805675&partnerID=8YFLogxK

M3 - Article

C2 - 9210687

AN - SCOPUS:0030805675

VL - 41

SP - 1571

EP - 1574

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -